Danaher To Acquire Masimo Corporation

Danaher Corporation, a world subject and exertion innovator, announced coming that it has entered into a definitive statement to get Masimo Corporation a starring specialty diagnostics supplier of beat oximetry and different diligent monitoring solutions, chiefly successful acute attraction settings. Under nan position of nan agreement, Danaher will get each of nan outstanding shares of Masimo communal banal for $180 per stock successful cash, aliases a full endeavor worth of astir $9.9 cardinal including assumed indebtedness and nett of acquired cash. This represents a transaction aggregate of astir 18x estimated 2027 EBITDA, aliases 15x 2027 estimated EBITDA including nan afloat use of expected yearly synergies.

We are excited to invited nan Masimo squad to Danaher. We've followed this innovative institution for galore years and spot it arsenic an exceptional strategical fresh for Danaher. Masimo is simply a leader successful beat oximetry and different diligent monitoring solutions, which mixed pinch its trusted marque and differentiated technology, will greatly fortify our diagnostics franchise. With nan Danaher Business System and our world scale, we spot opportunities to grow Masimo's scope and proceed improving outcomes for patients, peculiarly those successful acute attraction settings."

Rainer M. Blair, President and Chief Executive Officer, Danaher

Julie Sawyer Montgomery, Executive Vice President for Diagnostics, Danaher, said: "Masimo's precocious sensor exertion and AI-enabled monitoring bring powerful caller capabilities to our diagnostics portfolio. Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and amended determination making successful captious settings."

Upon completion of nan transaction, Masimo will beryllium a standalone operating institution wrong Danaher's Diagnostics conception on pinch Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics. Masimo is expected to beryllium accretive to adjusted diluted nett net per communal stock by $0.15 to $0.20 in nan first afloat twelvemonth and approximately $0.70 in nan 5th afloat twelvemonth pursuing completion of nan acquisition. Masimo is expected to present high-single digit halfway gross maturation complete nan long-term, accelerating Danaher's Diagnostics conception halfway gross maturation profile.

Under Danaher's ownership, Masimo is expected to make EBITDA of much than $530 million in 2027. Additionally, Danaher expects to recognize much than $125 million of yearly costs synergies and much than $50 million of yearly gross synergies by nan 5th afloat twelvemonth pursuing completion of nan acquisition.

The transaction is anticipated to adjacent successful nan 2nd half of 2026 and is taxable to customary conditions, including receipt of applicable regulatory clearances and Masimo shareholder approval. Danaher expects to money nan acquisition utilizing rate connected manus and proceeds from indebtedness financing.

Citi acted arsenic financial advisor to Danaher and Goldman Sachs provided advisory support. Kirkland & Ellis LLP served arsenic ineligible advisor to Danaher successful relationship pinch nan Transaction.

Core gross growth, adjusted diluted nett net per communal stock and EBITDA are non-GAAP measures; please spot "Non-GAAP Measures" beneath for further information.